EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales

Ying Fu, Yufeng Zhu, Feng Zhao, Bingyan Yao, Yunsong Yu, Jun Zhang, Qiong Chen

Infection and Drug Resistance · 2024-09 · Volume 17 · 3851-3861

DOI: 10.2147/idr.s474150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infection and Drug Resistance, 2024-09. Verfasst von Ying Fu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Our aim was to elucidate the resistance mechanisms and assess the combined synergistic and bactericidal activities of aztreonam in combination with ceftazidime/avibactam (CZA), meropenem/vaborbactam (MEV), and imipenem/relebactam (IMR) against Enterobacterales strains producing dual carbapenemases.

Methods

Species identification, antimicrobial susceptibility testing and determination of carbapenemase type were performed for these strains. Plasmid sizes, plasmid conjugation abilities and the localization of carbapenemase genes were investigated. Whole-genome sequencing was performed for all strains and their molecular characteristics were analyzed. In vitro synergistic and bactericidal activities of the combination of aztreonam with CZA, MEV and IMR against these strains were determined using checkerboard assay and time-kill curve assay.

Results

A total of 12 Enterobacterales strains producing dual-carbapenemases were collected, including nine K. pneumoniae, two P. rettgeri, and one E. hormaechei. The most common dual-carbapenemase gene pattern observed was bla (KPC-2+NDM-5) (n=4), followed by bla KPC-2+IMP-26 (n=3), bla (KPC-2+NDM-1) (n=2), bla (KPC-2+IMP-4) (n=1), bla (NDM-1+IMP-4) (n=1) and bla (KPC-2+KPC-2) (n=1). In each strain, the carbapenemase genes were found to be located on two distinct plasmids which were capable of conjugating from the original strain to the receipt strain E. coli J53. The results of the checkerboard synergy analysis consistently revealed good synergistic effects of the combination of ATM with CZA, MEV and IMR. Except for one strain, all strains exhibited significant synergistic activity and bactericidal activity between 2 and 8 hours.

Conclusion

Dual-carbapenemase-producing Enterobacterales posed a significant threat to clinical anti-infection treatment. However, the combination of ATM with innovative β-lactam/β-lactamase inhibitor compounds had proven to be an effective treatment option.

Schlagwörter

Stichwörter der Autor:innen

aztreonamcheckerboard assaydual-carbapenemase-producing enterobacteralestime-kill curveβ‑lactam/β‑lactamase inhibitor combinations

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
  • Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
  • Department of Clinical Laboratory, Hangzhou Xixi Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, People's Republic of China.
  • Department of Clinical Laboratory, Zhejiang University Sir Run Run Shaw Alar Hospital, Alar, Xinjiang province, People's Republic of China.
  • Department of Infectious Diseases, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Province, People's Republic of China.
  • Department of Clinical Laboratory, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang Province, People's Republic of China.

Zitieren

APA

Fu, Y., Zhu, Y., Zhao, F., Yao, B., Yu, Y., Zhang, J., & Chen, Q. (2024). In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales. Infection and Drug Resistance, Volume 17, 3851-3861. https://doi.org/10.2147/idr.s474150

Vancouver

Fu Y, Zhu Y, Zhao F, Yao B, Yu Y, Zhang J, et al. In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales. Infection and Drug Resistance. 2024;Volume 17:3851-3861. doi:10.2147/idr.s474150

BibTeX
@article{Fu2024,
  author = {Fu, Ying and Zhu, Yufeng and Zhao, Feng and Yao, Bingyan and Yu, Yunsong and Zhang, Jun and Chen, Qiong},
  title = {In vitro Synergistic and Bactericidal Effects of Aztreonam in Combination with Ceftazidime/ Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam Against Dual-Carbapenemase-Producing Enterobacterales},
  journal = {Infection and Drug Resistance},
  year = {2024},
  volume = {Volume 17},
  pages = {3851--3861},
  doi = {10.2147/idr.s474150}
}
Kostenlos starten →